US 11,932,703 B2
Anti-ROR1 antibody and ROR1-targeting engineered cells
Vita Golubovskaya, Pinole, CA (US); and Lijun Wu, Albany, CA (US)
Assigned to Caribou Biosciences, Inc.
Filed by Caribou Biosciences, Inc., Berkeley, CA (US)
Filed on May 22, 2023, as Appl. No. 18/321,655.
Claims priority of provisional application 63/365,230, filed on May 24, 2022.
Prior Publication US 2023/0383009 A1, Nov. 30, 2023
Int. Cl. C07K 16/40 (2006.01); C07K 14/725 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 14/7051 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 18 Claims
 
1. An anti-human ROR1 antibody or an antigen-binding fragment thereof comprising VH having an amino acid sequence at least 90% identical to SEQ ID NO: 2 and VL having an amino acid sequence at least 90% identical to SEQ ID NO: 3, the antibody or antigen-binding fragment comprising complementarity determining regions (CDRs) in the VH and the VL, wherein a CDR1 of the VH comprises the sequence TYA, a CDR2 of the VH comprises SEO ID NO: 41, a CDR3 of the VH comprises SEO ID NO: 42, a CDR1 of the VL comprises SEQ ID NO: 43, a CDR2 of the VL comprises the sequence RAN, and a CDR3 of the VL comprises SEQ ID NO: 45.